Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model

Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with heart failure. The potential for a pharmacokinetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Trivedi, Ashit, Sohn, Winnie, Kulkarni, Priyanka, Jafarinasabian, Pegah, Zhang, Hanze, Spring, Marintan, Flach, Stephen, Abbasi, Siddique, Wahlstrom, Jan, Lee, Edward, Dutta, Sandeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604240/
https://www.ncbi.nlm.nih.gov/pubmed/34415673
http://dx.doi.org/10.1111/cts.13118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604240/
https://www.ncbi.nlm.nih.gov/pubmed/34415673
http://dx.doi.org/10.1111/cts.13118

Ejemplares similares